Associate Editor, Ophthalmology Times
AMA adopts new policy to ensure diversity in clinical trials and research
June 14th 2024Under the new policy, grant-making entities will be encouraged to fund post-market research investigating pharmacodynamics and pharmacokinetics for generic drugs that did not adequately enroll women, and sexual and gender minority populations in their clinical trials.
Read More
IOP outcomes with intravitreal injection of aflibercept, 8mg and 2mg in patients with DME
June 3rd 2024Mark Barakat, MD, sat down with Ophthalmology Times to discuss intraocular pressure outcomes with intravitreal injection of aflibercept, 8mg and 2mg in patients with diabetic macular edema through week 48 of the phase 2/3 PHOTON trial.
Read More
A post hoc analysis of the phase 2/3 PHOTON trial
June 2nd 2024Sean Adrean, MD, FAAO, sat down with Ophthalmology Times to discuss a post hoc analysis of the phase 2/3 PHOTON trial and the outcomes of patients with DME and baseline BCVA of 20/50 or worse or 20/40 or better who were treated with aflibercept 8 mg and 2 mg.
Read More
Impact of baseline CRT on vision among patients with DME
June 1st 2024Deepak Sambhara, MD, sat down with Ophthalmology Times to discuss the impact of baseline central retinal thickness (CRT) on vision among patients with diabetic macular edema (DME), as a post hoc analysis of the phase 2/3 PHOTON trial.
Read More